Lack of resistance of Plasmodium falciparum to dihydroartemisinin in Uganda based on parasitogolgical and molecular assays

  • Roland A. Cooper
  • , Melissa D. Conrad
  • , Quentin D. Watson
  • , Stephanie J. Huezo
  • , Harriet Ninsiima
  • , Patrick Tumwebaze
  • , Samuel L. Nsobya
  • , Philip J. Rosenthal

Research output: Contribution to conferencePresentation

Abstract

  • Artemisinin-­‐based combination therapy is now standard treatment for falciparum malaria. However, this regimen is threatened by resistance to artemisinins, manifest as delayed clearance of parasitemia after therapy, in southeast Asia.
  • Artemisinin resistance in southeast Asia is associated with increased parasitemias in culture, compared to those in sensi0ve parasites, 72 hours a=er a 6 hour pulse with 700 nM dihydroartemisinin (DHA), and with propeller domain polymorphisms in the Plasmodium falciparum kelch (K13; PF3D7_1343700) gene

  • Given that artemether/lumefantrine has been adopted as standard therapy for malaria within the last decade in Uganda, we characterized artemisinin sensiBvity in fresh P. falciparum isolates from Kampala using ex vivo ring-­‐stage survival and IC50 assays. We also assessed the K13 gene for polymorphisms.

Original languageAmerican English
StatePublished - Oct 25 2015
EventAmerican Society of Tropical Medicine and Hygiene Annual Conference - Philadelphia, United States
Duration: Oct 25 2015Oct 29 2015
Conference number: 64th

Conference

ConferenceAmerican Society of Tropical Medicine and Hygiene Annual Conference
Abbreviated titleASTMH2015
Country/TerritoryUnited States
CityPhiladelphia
Period10/25/1510/29/15

Keywords

  • malaria
  • artemisinin

Disciplines

  • Life Sciences
  • Medicinal Chemistry and Pharmaceutics
  • Parasitic Diseases
  • Pharmacology, Toxicology and Environmental Health

Cite this